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Problems Associated with Community-Based Parenteral
Anti-Infective Therapy with Intravenous Ganciclovir for
Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic
Stem Cell Transplant Recipients
S. Mossad1,∗, N. Shrestha2, S. Rehm2, R. Avery2, B. Bolwell 2
1 Cleveland Clinic Foundation, Cleveland, OH, USA
2 Cleveland Clinic, Cleveland, OH, USA
Background: Our center utilized Cytomegalovirus (CMV)
prophylaxis with intravenous ganciclovir (IV GCV) in allo-
geneic hematopoietic stem cell transplant (allo HSCT)
recipients starting from engraftment to day +100. Most
of this regimen was administered as communitybased par-
enteral anti-infective therapy (CoPAT). Surveillance CMV
DNA detection by hybrid capture assay was done weekly
through day +100 and at varying intervals thereafter.
Methods: Retrospective review of the CoPAT database
and electronic medical records to evaluate adherence to this
protocol. Events were followed for 6 months from HSCT.
Results: 66 patients underwent allo HSCT from 5/07 to
6/08. Demographics were similar in patients who received
any prophylactic IV GCV (21 [32%]) and those who did not
(45 [68%]. 36 patients did not receive CoPAT for appropri-
ate reasons: CMV IgG donor negative & recipient negative
(19), delayed engraftment (5), relapse of underlying disease
(5), death within 100 days of HSCT (5), and refractory dis-
ease (2). Protocol deviation occurred in 23 patients (35%): IV
GCV was not started due to physician or patient choice (5),
was started appropriately, but stopped before D +100 due
to physician or patient choice (4), was started for treat-
ment of CMV viremia in a patient who should have been
on prophylactic IV GCV before that point in time (8), and
replacement of prophylactic IV GCV with oral valganciclovir
(6). Other reasons for early discontinuation of prophylactic
IV GCV before D +100 were leucopenia (6) and renal insufﬁ-
ciency (2). Median time from HSCT to starting CoPAT was 41
days. Median CoPAT duration was 45 days. Of the 30 appro-
priate candidates for prophylaxis, only 3 (10%) received the
complete prophylaxis course from engraftment through day
+100. In this nonrandomized study, the incidence of CMV
viremia, peak viral load (VL) and graftversus-host disease
(GVHD) were not signiﬁcantly different between prophy-
laxed, partially prophylaxed, and unprophylaxed groups.
Conclusion: In practice it proved to be difﬁcult to admin-
ister and complete the IV GCV prophylaxis course. Reasons
for this included delayed engraftment, relapsed or refrac-
tory underlying diseases, physician or patient individual
choices, leucopenia, and renal insufﬁciency. This study illus-
trates the importance of assessing prophylaxis strategies in
the context of actual clinical care. Valganciclovir; the L-valyl
ester of GCV is 60% orally bioavailable; representing a more
convenient and effective preventive alternative. Thus, in
1/09 we changed our CMV preventive strategy from universal
prophylaxis to preemptive therapy with valganciclovir.
doi:10.1016/j.ijid.2010.02.645
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description of the pathogenesis associated with piri-
al virus (an arenavirus) infection in the Syrian golden
amster
. Stammen ∗, J. Garver, S. Sarrazine, E. Vela
Battelle, Columbus, OH, USA
Background: Arenaviruses are rodent-borne agents and
ome are capable of causing hemorrhagic fever in humans.
hese viruses cause acute or persistent infection in a
iverse range of animals. Research involving arenaviruses
hat induce hemorrhagic fever is normally performed in
BSL-4 laboratory environment. However, BSL-2/3 are-
aviruses that cause hemorrhagic fever in animals may be
sed as a surrogate model system to screen potential vac-
ines and/or therapeutics. Pirital virus (PIRV) is a BSL-3 New
orld arenavirus that induces hemorrhagic fever manifesta-
ions in the Syrian golden hamster model. This model can be
tilized to screen and test vaccines and therapeutics.
Methods: Female Syrian golden implanted with teleme-
ry units measuring temperature and activity were followed
or 14 days post-challenge. Clinical signs of disease were
onitored. Viral titers in tissues, viremia, clinical chemistry,
ematology, and coagulation parameters and analyzed.
Results: Intraperitoneal infection of female Syrian golden
amsters with PIRV led to a speciﬁc disease progression
nvolving fever, loss of weight, lethargy, petechial rashes,
uddled posture, rufﬂed fur, epistaxis, and orbital hemor-
haging. Animals surviving to the later stages of disease
xhibited whole body tremors, loss of balance, shaking, hind
imb paralysis, and rectal hemorrhaging. PIRV infection in
amsters results in 100%mortality in 6-8 days after challenge
nd analyses of tissues resulted in measureable viremia and
iral titers in the adrenals, lymph nodes, intestines, kidney,
iver, and brain. Changes in clinical chemistry parameters
uggest liver and kidney damage while coagulation param-
ters demonstrate a disruption of coagulation and clotting.
ematology data demonstrate an increase in white blood
ell (WBC) and an increase or stabilization of thrombocytic
ounts.
Conclusion: In all, this has led to a description of a
emorrhagic fever model to study arenavirus hemorrhagic
ever pathogenesis and can be used as a cost effective,
ime-efﬁcient BSL-3 surrogate to screen various antiviral
herapeutics and/or vaccine strategies.
oi:10.1016/j.ijid.2010.02.646
4.016
odiﬁcation of the type I interferon and proinﬂammatory
ytokine responses by enterovirus 71
.-P. Lee1,∗, S.-W. Huang1, Y.-F. Wang2, C.-K. Yu1
National Cheng Kung University, Tainan City, Taiwan, R.O.C
National Health Research Institute, Tainan City, Taiwan,
.O.CBackground: Enterovirus 71 (EV71) is a neutropic virus
argeting the brain stem that may result in severe seque-
ae including paralysis and pulmonary edema (PE). Type
interferons (IFNs) represent an essential innate defense
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echanism for controlling EV71 infection. Inﬂammatory
esponse with induction of toxic inﬂammatory cytokines has
een considered as an essential component of the patho-
enesis of EV71, especially the development of neurogenic
E.
Methods: In this study, the role of the type I IFN and proin-
ammatory cytokine responses on the disease development
nd mechanisms of viral evasion were investigated by using
murine model with mouse-adapted EV71 strain.
Results: After EV71 inoculation, the animals devel-
ped viremia, limb paralysis, pulmonary dysfunction, and
mphysema with a signiﬁcant increase of interleukin (IL)-6,
onocyte chemoattractant protein-1, tumor necrosis fac-
or and IFN-/, but not IL-10, IL-12, IL-13, and type I IFNs
n serum and brain. We assumed that sufﬁcient amounts
f PE-associated cytokines (i.e., IL-6, IL-13, and IFN-/) may
e required for the development of EV71-induced PE. The
esults showed that EV71-infected mice with post-treatment
f IL-6, IL-13, and IFN-/developed PE and severe emphysema
ccompanying with a more severe pulmonary dysfunction
han EV71-infected, cytokine non-treated mice. Further-
ore, we observed that mice inoculated with EV71 produced
signiﬁcant lower amount of serum type I IFNs than those
noculated with poly (I:C), adenovirus type V, or Coxsackie
3 virus (CB3). EV71 preinfection abolished both poly (I:C)
nd CB3 induced-type I IFN production, and decreased the
ercentage of IFN-producing plasmacytoid dendritic cells in
lood of CB3-infected mice. In addition, a pre-incubation
f EV71 also reduced poly (I:C) induced-type I IFN produc-
ion of murine monocyte/macrophage cell line, RAW264.7.
he inhibitory effect of EV71 on type I IFN production
as contributed by 3C protease that was proven using
ver-expression systems either in RAW264.7 cell or adult
ouse.
Conclusion: In conclusion, EV71 may block type I IFN syn-
hesis through 3C protease to interfere with host innate
efence, and on the other hand, trigger proinﬂammatory
ytokine responses to promote PE development.
oi:10.1016/j.ijid.2010.02.647
4.017
he study of epidemiological data of varicella and its com-
lications in Albanian children
. Hoxha1,∗, E. Kallfa-Foto1, G. Lito1, R. Petrela1, A.
imaku2
University Hospital Center Mother Theresa Tirana, Alba-
ia, Tirana, Albania
Institute Public Health, Tirana, Albania
Background: Varicella is a serious diseases especially for
ts complications and even death,may occur in healthy chil-
ren. Complication have been estimated at a rate of 29.2 per
0000.The serious problem of varicella are reduced after
ntroduced of the vaccine against varicella. The aims of
his study was to show epidemiological data,risk factors and
omplications of varicella in the Albanian children.Methods: This was a retrospective study and in this study
ere included 68 children aged 0 to 14 years old admit-
ed in University Hospital Center during January 2004 to
ecember 2008.Epidemiological data analysed were: sex,
p
t
s
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ge,origin,length of hospitalization,risk factors and compli-
ations.
Results: The mean length of hospitalization was 5.2
ays. Age-group most affected was 1-6 years old with
0 cases or 44.12%,followed by children aged 7-14 years
ld with 22 cases or 32.3%.47 cases or 69.1% were male
nd there were no difference for origin.We observed
his complications: bacterial overinfections: 22 cases or
2.36%(skin and soft tissue infectious caused by S.aureus
nd S. pyogenes) 4 oteoarthritis,neurological complications:
cerebellitis,2 encephalitis,3 status epilepticus, 1 neuri-
is, 12 varicella pneumonia,1 hepatitis, 1 thrombocytopenic
urpura,1 hemolitic anemia. 18 cases or26.45% under one
ears old presented enteritis.Acyclovir was used in 26 cases
r 38.2%.(mainly complicated). We observed risk factors in
cases or (11.8%) as: 3 leucemia,5 atopic dermatitis.
Conclusion: Varicella still remains a frequent infection of
hildhood,which often is followed by serious complications.
he results of this study can contribute to evaluating the
ptions for varicella vaccination.
oi:10.1016/j.ijid.2010.02.648
4.018
atent manifestations in the US Congenital Rubella Syn-
rome (CRS) Population
. Armstrong
Molloy College, Rockville Centre, NY, USA
Background: Since rubella and congenital rubella syn-
rome (CRS) have not been globally eradicated and
opulations who do not vaccinate continue to persist,
ncreasing knowledge about adults with CRS remains of great
mportance. This study investigated the latent CRS manifes-
ations of 174 adults with CRS in the United States, born
efore 1987.
Methods: Cross sectional design. In this study, Helen
eller National Center’s (HKNC) registry was used to identify
ndividuals born with CRS in the United States. Established
hrough an Act of Congress, HKNC is mandated to main-
ain a national registry of persons who are deaf-blind. The
ational database, located at HKNC in New York contains
ersonal (race, marital status, residential status, educa-
ion and employment) and medical (etiology, diagnostic
nd comorbidities) information on more than 10, 000 deaf-
lind individuals with birth dates ranging from 1930-present.
ccording to HKNC, there are approximately 1000 deaf blind
ndividuals 21 and older who are listed as having CRS (HKNC,
006). According to the CDC, this cohort is the result of the
963-1965 rubella epidemic. In addition, the registry lists
13 CRS children, ages birth to 21.
Results: The survey reported the prevalence of medical
isorders including diabetes, cardiac and thyroid dysfunc-
ion and glaucoma. Additionally, psychological symptoms
uch as autisticlike behavior, mood disorder and aggressive
ehavior were reported
Conclusion: CRS is characterized by multiple defects,
articularly to the heart, eyes, ears and brain. In utero,
he rubella-virus can damage the immune system and ves-
els which is a harmful starting point for several diseases
nce the CRS-individual ages. CRS individuals are develop-
